

Ministry of Health

OHIP, Pharmaceuticals and Devices Division

Drug Submission Status

Report for March 2022

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via a OPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Sanis Health Inc.	Mometasone	Nasonex	MOMETASONE FUROATE	50 mcg/actuation	spray	02519127
Apotex Inc.	Desvenlafaxine	Pristiq	DESVENLAFAXINE	50 mg	ER tablet	02467119
Apotex Inc.	Desvenlafaxine	Pristiq	DESVENLAFAXINE	100 mg	ER tablet	02467127
Taro Pharmaceuticals Inc.	Taro-Acyclovir	Zovirax	ACYCLOVIR	5% w/w	topical ointment	02522306
Nora Pharma	NRA-Tramadol/ACET	Tramacet	TRAMADOL HCL & ACETAMINOPHEN	37.5 mg & 325 mg	tablet	02469650
Sandoz Canada Inc.	Ceftriaxone Sodium for Injection BP	Rocephin	CEFTRIAZONE DISODIUM	10 mg	powder for solution, IV	02292297
Teva Canada Limited	Teva-Desvenlafaxine	Pristiq	DESVENLAFAXINE SUCCINATE	50 mg	ER tablet	02458217

Teva Canada Limited	Teva-Desvenlafaxine	Pristiq	DESVENLAFAXINE SUCCINATE	100 mg	ER tablet	02458225
---------------------	---------------------	---------	--------------------------	--------	-----------	----------